Globus Medical (NYSE: GMED) has recently received a number of price target changes and ratings updates:

  • 10/4/2017 – Globus Medical was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. “
  • 9/26/2017 – Globus Medical is now covered by analysts at Needham & Company LLC. They set a “hold” rating on the stock. They wrote, “GMED’s core spine organic growth has slowed though we expect some improvement in 2018 due to sales force enhancements. Its Emerging Technologies business should begin to add to growth in 2018 as well. But even accounting for this, we’re concerned that consensus 2018 estimates may be too high. And we believe that GMED’s earnings growth is going to be mostly driven by revenue growth.””
  • 9/22/2017 – Globus Medical had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $38.00 price target on the stock.
  • 9/18/2017 – Globus Medical was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 9/14/2017 – Globus Medical was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. “
  • 9/7/2017 – Globus Medical is now covered by analysts at BTIG Research. They set a “buy” rating and a $37.00 price target on the stock.
  • 9/7/2017 – Globus Medical was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 9/4/2017 – Globus Medical was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. “
  • 8/30/2017 – Globus Medical had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 8/29/2017 – Globus Medical was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. “
  • 8/26/2017 – Globus Medical was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/18/2017 – Globus Medical had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $37.00 price target on the stock.
  • 8/9/2017 – Globus Medical had its “underweight” rating reaffirmed by analysts at Barclays PLC. They now have a $28.00 price target on the stock, down previously from $30.00.

Shares of Globus Medical, Inc. (NYSE:GMED) traded up 0.03% during mid-day trading on Thursday, hitting $31.03. 91,464 shares of the stock traded hands. The company has a market cap of $2.99 billion, a price-to-earnings ratio of 27.95 and a beta of 0.56. Globus Medical, Inc. has a 52 week low of $19.25 and a 52 week high of $34.03. The stock has a 50-day moving average of $29.85 and a 200-day moving average of $30.86.

Globus Medical (NYSE:GMED) last released its earnings results on Wednesday, August 2nd. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.30 by $0.02. Globus Medical had a net margin of 18.12% and a return on equity of 13.99%. The company had revenue of $152.39 million during the quarter, compared to the consensus estimate of $150.94 million. During the same quarter in the prior year, the firm earned $0.29 EPS. The company’s revenue was up 10.8% compared to the same quarter last year. Analysts anticipate that Globus Medical, Inc. will post $1.27 EPS for the current year.

In other Globus Medical news, insider A Brett Murphy sold 15,000 shares of the stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $29.99, for a total value of $449,850.00. Following the completion of the sale, the insider now owns 101,217 shares in the company, valued at approximately $3,035,497.83. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 28.21% of the stock is owned by corporate insiders.

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Receive News & Ratings for Globus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.